Try our beta test site
406 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"
Show Display Options
Rank Status Study
21 Terminated A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
22 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
23 Withdrawn Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Other: Placebo
24 Completed
Has Results
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Device: Rebif Rebidose;   Device: Rebiject II
25 Withdrawn Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: RNS60 125 ml;   Drug: RNS60 250 ml;   Drug: Interferon beta 1a
26 Completed Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
27 Active, not recruiting A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA);   Other: Placebo
28 Completed
Has Results
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: abatacept;   Drug: Placebo
29 Terminated Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Device: RebiSmart®2.0;   Device: MSdialog™
30 Terminated Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1b
31 Recruiting Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: IL2;   Drug: Placebo
32 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)
33 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
34 Active, not recruiting Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
35 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
36 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
37 Completed Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Device: Rebif® via Rebiject™Mini;   Device: Rebif® via manual injections
38 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Ocrelizumab
39 Completed An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
40 Completed Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment;   Drug: untreated to atorvastatin treatment

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.